Targeting c-MYC G-Quadruplexes for Cancer Treatment with Small Molecules
Novel therapies are required due to the rising cancer burden. Conventional chemotherapeutics tend to be particularly toxic, but there is a promising alternative for oncogenes, such as c-MYC. Often overexpressed in many cancer types, the potential c-MYC oncogene seems essential to the development of cancer. Targeting c-MYC protein directly was limited, but these DNA structures composed of guanine-rich sequences suppress c-MYC transcription. This review discusses recent advances in developing small compounds that selectively bind to and stabilize c-MYC G-quadruplexes (G4). These molecules have also shown promise for the inhibition of c-MYC signaling and inhibition of tumor growth, suggesting that G-quadruplex targeting could be a promising therapeutic for cancer.
Authors
- Thumpati Prasanth (ORCID: https://orcid.org/0000-0002-6609-2863)
- Santosh Kumar Singh (ORCID: https://orcid.org/0000-0003-0575-9019)
- Kakarla Ramakrishna (ORCID: https://orcid.org/0000-0003-2067-1410)
- Sachchida Nand (ORCID: https://orcid.org/0000-0001-8418-9549)
- Chandrabhan Prajapati (ORCID: https://orcid.org/0000-0003-0589-0578)
Institutions
- Virginia Commonwealth University (US)
- Institute of Medical Sciences (IN)
- Koneru Lakshmaiah Education Foundation (IN)
- Banaras Hindu University (IN)
Publication Details
- Journal
- Scientia Pharmaceutica
- Published
- 2025-01-22
- DOI
- https://doi.org/10.3390/scipharm93010006
- Citations
- 55
- Primary Topic
- DNA and Nucleic Acid Chemistry
- Type
- article
- Field-Weighted Citation Impact
- 44.33
Funders
- National Institute of Pharmaceutical Education and Research, Raebareli